Company / Cash per Share
Myriad Genetics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.84
FY2025
5-year range
$0.77 / $3.65
FY2021-FY2025
Trend
+43.9%
vs FY2024
Sector context
#113 of 205
Health Care
What the data says
At $1.84, Myriad Genetics, Inc.'s cash per share ranks #113 of 205 in the Health Care sector. Cash per Share has fluctuated over the past 10 years, ranging from $0.77 in FY2022 to $3.65 in FY2021.
Based on SEC 10-K filings.
1.84 in FY2025 with a 5-year CAGR of -5.1%.
Improved from $1.75 to $1.84 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +33.5%
- 5-Year CAGR
- -5.1%
- 10-Year CAGR
- -
Sector benchmark
#113 of 205 in Health CareTop 55% of 205This company $1.84 Sector average $67.98
▼
-97.3% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 43.9% year-over-year.
- Ranks #113 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2021.
- Lowest cash per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.84 | +43.9% |
| FY2024 | $1.28 | -26.9% |
| FY2023 | $1.75 | +126.3% |
| FY2022 | $0.77 | -78.8% |
| FY2021 | $3.65 | +52.3% |
| FY2020 | $2.39 | +77.4% |
| FY2019 | $1.35 | -16.2% |
| FY2018 | $1.61 | +15.5% |
| FY2017 | $1.39 | +63.9% |
| FY2016 | $0.85 | +9.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026